Objective:
To define benchmark cutoffs for redo liver transplantation (redo-LT).
Background:
In the era of organ shortage, redo-LT is frequently discussed in terms of expected poor outcome and wasteful resources. However, there is a lack of benchmark data to reliably evaluate outcomes after redo-LT.
Methods:
We collected data on redo-LT between January 2010 and December 2018 from 22 high-volume transplant centers. Benchmark cases were defined as recipients with model of end stage liver disease (MELD) score ≤25, absence of portal vein thrombosis, no mechanical ventilation at the time of surgery, receiving a graft from a donor after brain death. Also, high-urgent priority and early redo-LT including those for primary nonfunction (PNF) or hepatic artery thrombosis were excluded. Benchmark cutoffs were derived from the 75th percentile of the medians of all benchmark centers.
Results:
Of 1110 redo-LT, 373 (34%) cases qualified as benchmark cases. Among these cases, the rate of postoperative complications until discharge was 76%, and increased up to 87% at 1-year, respectively. One-year overall survival rate was excellent with 90%. Benchmark cutoffs included Comprehensive Complication Index CCI® at 1-year of ≤72, and in-hospital and 1-year mortality rates of ≤13% and ≤15%, respectively. In contrast, patients who received a redo-LT for PNF showed worse outcomes with some values dramatically outside the redo-LT benchmarks.
Conclusion:
This study shows that redo-LT achieves good outcome when looking at benchmark scenarios. However, this figure changes in high-risk redo-LT, as for example in PNF. This analysis objectifies for the first-time results and efforts for redo-LT and can serve as a basis for discussion about the use of scarce resources.
BackgroundCommon bile duct injuries (CBDIs) remains a rare but serious complication in children undergoing laparoscopic cholecystectomy (LC), with an incidence of 0.44%. In severe lesions, a major liver resection may be necessary as a definitive treatment. The current principles for safe hepatectomy are mainly focused on the liver parenchyma that remains after resection. Therefore, one of the main factors related to posthepatectomy hepatic insufficiency is the quantity and quality of the future liver remnant (FLR). To achieve an optimal FLR, techniques such as portal vein embolization (PVE) are available.Case presentationWe present the case of a 5-year-old child with a severe CBDI after LC, treated with preoperative PVE followed by a right hepatectomy as definitive treatment. No reports of liver resections and PVE are described in the literature concerning the pediatric population.
Identificar correctamente las glándulas paratiroides antes de un procedimiento es fundamental para realizar una cirugía mínimamente invasiva. Pruebas de primera línea con resultados discordantes o negativos subrayan la necesidad de métodos de imagen más precisos. Luego de una revisión sistemática encontramos que el PET/TC con 18F-fluorocolina resulta útil como prueba complementaria ante estos casos.
El carcinoma escamoso de lengua es la lesión maligna más frecuente de la cavidad oral. El hallazgo de metástasis en este tipo de neoplasias se considera el principal factor de mal pronóstico con efecto marcado en la sobrevida global del paciente. La progresión habitual suele ser locorregional, en el lecho quirúrgico o a nivel ganglionar, siendo poco frecuente el hallazgo de afectación sistémica.
Se presenta el caso de un paciente masculino de 40 años de edad con diagnóstico de cáncer de lengua y metástasis renales bilaterales, a los 11 meses del diagnóstico inicial. La biología agresiva, la localización extremadamente rara de las metástasis y el pronóstico sombrío ilustran un caso inusual que resalta la importancia de su publicación.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.